Rakuten Aspyrian Revenue and Competitors
Estimated Revenue & Valuation
- Rakuten Aspyrian's estimated annual revenue is currently $29.6M per year.
- Rakuten Aspyrian received $134.0M in venture funding in December 2018.
- Rakuten Aspyrian's estimated revenue per employee is $193,750
- Rakuten Aspyrian's total funding is $618.6M.
Employee Data
- Rakuten Aspyrian has 153 Employees.
- Rakuten Aspyrian grew their employee count by 61% last year.
Rakuten Aspyrian's People
Name | Title | Email/Phone |
---|---|---|
1 | Vp, Global People Operations | Reveal Email/Phone |
2 | VP Finance | Reveal Email/Phone |
3 | VP Clinical Development, Rakuten Aspyrian Japan K.K | Reveal Email/Phone |
4 | Chief Technology Officer | Reveal Email/Phone |
5 | President & COO | Reveal Email/Phone |
6 | Dir, Corporate & Business Development | Reveal Email/Phone |
7 | DIR Strategic Planning/Operations/Head Asia Business Promotion, Rakuten Aspyrian Japan | Reveal Email/Phone |
Rakuten Aspyrian Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Rakuten Aspyrian?
Rakuten Aspyrian, Inc., is a privately funded clinical stage biotechnology company with offices in the USA, Japan and Germany. Since 2013, Rakuten Aspyrian has been developing new anticancer therapies based on the Photoimmunotherapy platform. Rakuten Aspyrian plans to become a fully integrated biopharma with research, development, and world-wide commercialization of therapies based on the Photoimmunotherapy platform. Our long-term objective is to commercialize a number of therapies based on Photoimmunotherapy to treat a broad range of solid tumor types as single agent and in combination with other immunomodulatory agents to generate robust and long lasting anticancer immunological responses. Rakuten Aspyrian is currently sponsoring a global Phase 3 multicenter clinical study for ASP-1929 to evaluate the efficacy and safety of ASP-1929 in patients with recurrent Head and Neck Cancer and additional Phase 2 studies to evaluate the safety and efficacy of ASP-1929 in patients with other cancer types. Given the rapid progression of the clinical studies, we are quickly expanding the team to support late stage pivotal clinical development and future commercialization of our products.
keywords:N/A$618.6M
Total Funding
153
Number of Employees
$29.6M
Revenue (est)
61%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Rakuten Aspyrian News
SAN MATEO, Calif., March 1, 2019 /PRNewswire/ -- Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer ...
Rakuten Aspyrian, a San Mateo, California, CA-based biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy platform, raised an additional $134m in a second tranche of its Series C financing, bringing the total amount raised to $284m. Bac ...
SAN FRANCISCO, Dec. 20, 2018 /PRNewswire/ -- Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer ...
SAN DIEGO, Dec. 17, 2018 /PRNewswire/ -- Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer therapies ...
San Diego-based biotechnology developer Rakuten Aspyrian announced last week that it has raised $150M for its efforts to develop treatments for head and neck cancer. According to Rakuten Aspyrian, the Series C funding round was led by Hiroshi Mikitani, the CEO of Japan's Rakuten. The company has ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $45M | 153 | -70% | $248.5M |
#2 | $5.7M | 153 | 18% | $791.4M |
#3 | $42.7M | 153 | 10% | N/A |
#4 | $29.8M | 154 | 15% | $134.1M |
#5 | $43M | 154 | 25% | N/A |
Rakuten Aspyrian Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2018-08-24 | $150.0M | C | Rakuten Inc | Article |
2018-12-21 | $134.0M | C | SBI Group | Article |